Trials / Completed
CompletedNCT01622231
Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 2 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
Safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will be evaluated. And secondarily, efficacy and systemic exposure of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluticasone furoate | 55 mcg/day, intranasal, 12 weeks |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2012-06-19
- Last updated
- 2017-01-09
- Results posted
- 2013-08-12
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01622231. Inclusion in this directory is not an endorsement.